MBX Biosciences (MBX) Cash from Financing Activities (2023 - 2026)
MBX Biosciences (MBX) reported Cash from Financing Activities of $87.4 million for Q1 2026, up 2185775.0% on a YoY basis from N/an in Q1 2025, and up 19862.33% sequentially from $438000.0 in Q4 2025.
MBX Biosciences (MBX) Cash from Financing Activities (2023 - 2026) Analysis & Trends
MBX Biosciences (MBX) has 4 years of Cash from Financing Activities data on file, last reported at $87.4 million in Q1 2026.
- For the quarter ending Q1 2026, Cash from Financing Activities rose 2185775.0% year-over-year to $87.4 million; the trailing twelve-month figure through Mar 2026 stood at $277.0 million (up 18.42% YoY), and the FY2025 full-year result was $189.6 million, down 19.01% from the prior year.
- Cash from Financing Activities grew to $87.4 million in Q1 2026, from $438000.0 in the prior quarter.
- In the past five years, Cash from Financing Activities ranged from a high of $235.8 million in Q3 2024 to a low of -$1.8 million in Q2 2024.
- A 4-year average of $51.1 million and a median of $310500.0 in 2024 frame the typical range for Cash from Financing Activities.
- Across the five-year window, Cash from Financing Activities slumped 794.74% in 2024 and surged 2185775.0% in 2026, its largest moves.
- Tracing MBX's Cash from Financing Activities over 4 years: stood at $19000.0 in 2023, then tumbled by 794.74% to -$132000.0 in 2024, then soared by 431.82% to $438000.0 in 2025, then surged by 19862.33% to $87.4 million in 2026.
- Business Quant data shows MBX's Cash from Financing Activities at $87.4 million in Q1 2026, $438000.0 in Q4 2025, and $187.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 30.14 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 68.63 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 9,311.16 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | -538.80 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | -802.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 238.74 Mn |
| 10 | MBX Biosciences | 2.96 Bn | 2.96 Bn | - | 87.44 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 87.44 Mn |
| Mar 31, 2026 | 87.44 Mn |
| Dec 31, 2025 | 438,000.00 |
| Dec 31, 2025 | 438,000.00 |
| Sep 30, 2025 | 187.82 Mn |
| Sep 30, 2025 | 187.82 Mn |
| Jun 30, 2025 | 1.33 Mn |
| Jun 30, 2025 | 1.33 Mn |
| Mar 31, 2025 | 4,000.00 |
| Mar 31, 2025 | 4,000.00 |
| Dec 31, 2024 | -132,000.00 |
| Dec 31, 2024 | -132,000.00 |
| Sep 30, 2024 | 235.81 Mn |
| Sep 30, 2024 | 235.81 Mn |
| Jun 30, 2024 | -1.76 Mn |
| Jun 30, 2024 | -1.76 Mn |
| Mar 31, 2024 | 183,000.00 |
| Mar 31, 2024 | 183,000.00 |
| Dec 31, 2023 | 19,000.00 |
| Dec 31, 2023 | 19,000.00 |